摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-苯磺酰氨基苯甲酸 | 28547-16-2

中文名称
4-苯磺酰氨基苯甲酸
中文别名
对-(苯基氨基磺酰基)苯甲酸;4-(苯磺酰基氨基)苯甲酸;苯甲酸,4-[(苯磺酰基)氨基]-
英文名称
4-(phenylsulfonamido)benzoic acid
英文别名
4-Benzenesulfonylaminobenzoic acid;4-(benzenesulfonamido)benzoic acid
4-苯磺酰氨基苯甲酸化学式
CAS
28547-16-2
化学式
C13H11NO4S
mdl
MFCD00531525
分子量
277.301
InChiKey
YAGOYAVZOJQMRT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    212 °C (decomp)
  • 沸点:
    487.8±47.0 °C(Predicted)
  • 密度:
    1.451±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.8
  • 重原子数:
    19
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    91.8
  • 氢给体数:
    2
  • 氢受体数:
    5

安全信息

  • 海关编码:
    2935009090
  • 危险性防范说明:
    P305+P351+P338,P280
  • 危险性描述:
    H317,H319
  • 储存条件:
    应存放在室温、干燥、密封的环境中。

SDS

SDS:9b0eff50a6af9311b2900f5ad99073f6
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 4-Benzenesulfonylaminobenzoic acid
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 4-Benzenesulfonylaminobenzoic acid
CAS number: 28547-16-2

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C13H11NO4S
Molecular weight: 277.3

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-苯磺酰氨基苯甲酸N,N'-羰基二咪唑盐酸羟胺 作用下, 以 四氢呋喃 为溶剂, 反应 1.0h, 生成 N-hydroxy-4-(phenylsulfonamido)benzamide
    参考文献:
    名称:
    异羟肟酸与苯磺酰胺:开发广谱金属-β-内酰胺酶抑制剂的有效支架
    摘要:
    鉴于金属β-内酰胺酶(MβLs)介导的β-内酰胺抗生素耐药性严重威胁人类健康,我们与苯磺酰胺一起设计并合成了19种异羟肟酸,对四种测试的MβLs ImiS、L1、VIM-2和IMP-1(IMP-1 上的6、13和18以及 VIM-2 上的 18除外),IC 50值分别在 0.6–9.4、1.3–27.4、5.4–43.7 和 5.2–49.7 µM 范围内,并恢复了头孢唑啉和美罗培南的抗菌活性,导致抗生素的 MIC 降低了 2-32 倍。化合物17对 L1 显示出可逆的竞争性抑制作用, K i值为 2.5 µM,并显着降低被表达 L1 的大肠杆菌感染的小鼠脾脏和肝脏中的细菌负荷。对接研究表明17通过磺酰胺基团的氧原子与VIM-2和CphA的Zn(II)紧密结合,但通过异羟肟酸基团的氧原子与L1的Zn(II)配位。这些研究表明,异羟肟酸与苯磺酰胺是开发 MβL 抑制剂的有效支架。
    DOI:
    10.1016/j.bioorg.2020.104436
  • 作为产物:
    描述:
    参考文献:
    名称:
    方便合成新型磺酰胺衍生物作为有前途的抗癌药
    摘要:
    新型磺酰胺衍生物是由易于获得的N-(4-乙酰基苯基)苯磺酰胺合成的(1)。1与苯肼在回流的乙醇中缩合,得到相应的苯hydr 2,然后将其加入Vilsmeier-Haack试剂(POCl 3 / DMF)中,得到4-甲酰基吡唑衍生物3。在碘存在下于130°C将1与硫脲融合,得到2-氨基噻唑衍生物4。用过量的N,N-二甲基甲酰胺二甲基乙缩醛回流1提供了烯胺酮5。已经研究了烯胺5对某些氮和碳亲核试剂的化学反应性,以获得带有磺酰胺部分的多官能杂芳族体系。此外,烯胺5发生Gewald反应,并在吗啉存在下与氰基乙酸乙酯和元素硫反应,生成2-氨基噻吩衍生物18。此外,还研究了5在合成4-(苯磺酰胺基)苯甲酸(19)中的效用。对合成的磺酰胺类药物进行了体外评估对两种人类细胞系MCF-7(乳腺癌细胞)和RPE-1(正常的视网膜色素上皮细胞)具有细胞毒活性。结果表明,化合物1-3,6-8,10,12B,18,
    DOI:
    10.1002/jhet.3849
点击查看最新优质反应信息

文献信息

  • Acylated 1<i>H</i>-1,2,4-Triazol-5-amines Targeting Human Coagulation Factor XIIa and Thrombin: Conventional and Microscale Synthesis, Anticoagulant Properties, and Mechanism of Action
    作者:Marvin Korff、Lukas Imberg、Jonas M. Will、Nico Bückreiß、Svetlana A. Kalinina、Benjamin M. Wenzel、Gregor A. Kastner、Constantin G. Daniliuc、Maximilian Barth、Ruzanna A. Ovsepyan、Kirill R. Butov、Hans-Ulrich Humpf、Matthias Lehr、Mikhail A. Panteleev、Antti Poso、Uwe Karst、Torsten Steinmetzer、Gerd Bendas、Dmitrii V. Kalinin
    DOI:10.1021/acs.jmedchem.0c01635
    日期:2020.11.12
    We herein report the conventional and microscale parallel synthesis of selective inhibitors of human blood coagulation factor XIIa and thrombin exhibiting a 1,2,4-triazol-5-amine scaffold. Structural variations of this scaffold allowed identifying derivative 21i, a potent 29 nM inhibitor of FXIIa, with improved selectivity over other tested serine proteases and also finding compound 21m with 27 nM
    我们在此报告了常规和微观并行合成的人类凝血因子XIIa和凝血酶的选择性抑制剂,这些抑制剂表现出1,2,4-三唑-5-胺骨架。该支架的结构变异允许鉴定衍生物21i(一种有效的FXIIa抑制剂29nM),具有比其他经过测试的丝氨酸蛋白酶更高的选择性,还可以发现化合物21m对凝血酶具有27 nM的抑制活性。首次证明酰化的1,2,4-三唑-5-胺具有抗凝特性,并具有影响凝血酶和癌细胞诱导的血小板凝集的能力。进行的质谱分析和分子建模使我们能够发现合成的抑制剂与FXIIa活性位点之间以前未知的相互作用,从而揭示了FXIIa抑制的机理细节。合成的化合物代表了开发新的抗血栓药物或化学工具以研究FXIIa和凝血酶在生理和病理过程中的作用的有希望的起点。
  • [EN] SULFONAMIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF<br/>[FR] COMPOSÉS SULFAMIDES, COMPOSITIONS PHARMACEUTIQUES ET LEURS UTILISATIONS
    申请人:EVOTEC AG
    公开号:WO2010130638A1
    公开(公告)日:2010-11-18
    Compounds are provided according to formula (1), wherein W, X, Z, R1, R2, R3, and ml are as defined herein. Provided compounds and pharmaceutical compositions thereof are useful for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non- limiting example, pain, inflammation, cognitive disorders, anxiety, depression, and others. Provided compounds and pharmaceutical compositions thereof are also useful for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non- limiting example immune-mediated disorders and autoimmune diseases, including multiple sclerosis, type-1 diabetes mellitus, type-2 diabetes mellitus, rheumatoid arthritis, psoriasis, contact dermatitis, obesity, systemic lupus erythematosus, graft-versus host disease, transplant rejection, and others.
    根据公式(1),提供的化合物中,其中W、X、Z、R1、R2、R3和ml的定义如本文所述。提供的化合物及其药物组合物对于预防和治疗包括人类在内的哺乳动物的各种疾病条件是有用的,包括但不限于疼痛、炎症、认知障碍、焦虑、抑郁等。提供的化合物及其药物组合物还对于预防和治疗包括人类在内的哺乳动物的各种疾病条件是有用的,包括但不限于免疫介导性疾病和自身免疫疾病,包括多发性硬化、1型糖尿病、2型糖尿病、类风湿性关节炎、牛皮癣、接触性皮炎、肥胖症、系统性红斑狼疮、移植物抗宿主病、移植排斥反应等。
  • Design, synthesis, and activity evaluation of broad-spectrum small-molecule inhibitors of anti-apoptotic Bcl-2 family proteins: Characteristics of broad-spectrum protein binding and its effects on anti-tumor activity
    作者:Can-Hui Zheng、Hui Yang、Meng Zhang、Shi-Hai Lu、Duo Shi、Juan Wang、Xiu-Hua Chen、Xiao-Hui Ren、Jia Liu、Jia-Guo Lv、Ju Zhu、You-Jun Zhou
    DOI:10.1016/j.bmcl.2011.11.101
    日期:2012.1
    than ABT-737 at inhibiting growth in multiple tumor cell lines known to express Bcl-xL, Bcl-2, and Mcl-1 proteins at high levels. Compounds B-11 and B-12 had the strongest anti-tumor activity of any compounds we produced. This study suggests that it is feasible to design small-molecule inhibitors based on the structure of Bim BH3, which shows broad-spectrum binding to Bcl-xL, Bcl-2, and Mcl-1 proteins
    在比较Bim BH3:Bcl-x L络合物和ABT-737:Bcl-x L络合物的结构的基础上,设计了一系列A类化合物。这些化合物具有ABT-737的基本骨架和Bim BH3的h2残基。在饱和诱变测定中,这些残基已显示出与Bim BH3的广谱结合特性有关。与作为Bcl-2蛋白家族抗凋亡成员的选择性抑制剂的ABT-737不同,A类化合物对目标蛋白具有广谱结合活性,类似于Bim BH3肽。然后通过修饰最有效的A类化合物的结构来合成B类化合物化合物A - 4。这些大多数B类化合物显示出比A类化合物更好的与靶蛋白的结合亲和力。他们还显示出比ABT-737更有效地抑制已知以高水平表达Bcl-x L,Bcl-2和Mcl-1蛋白的多种肿瘤细胞的生长。在我们生产的所有化合物中,化合物B - 11和B - 12具有最强的抗肿瘤活性。这项研究表明,根据Bim BH3的结构设计小分子抑制剂是可行的,该结构显示了与Bcl-x
  • THERAPEUTIC COMPOUNDS AND COMPOSITIONS
    申请人:Salituro Francesco G.
    公开号:US20100331307A1
    公开(公告)日:2010-12-30
    Compounds and compositions comprising compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer.
    本文描述了调节丙酮酸激酶M2(PKM2)的化合物和含有这些化合物的组合物。本文还描述了利用调节PKM2的化合物治疗癌症的方法。
  • BIO-POTENT SULFONAMIDES
    作者:Selvakumar Dineshkumar、Ganesamoorthy Thirunarayanan
    DOI:10.4067/s0717-97072019000104386
    日期:——
    Some 4-(substituted phenylsulfonamido)benzoic acids have been synthesized by fly-ash:H3PO3 nano catalyst catalyzed condensation of substituted benzenesulfonyl chlorides and 4-aminobenzoic acid in ultrasound irradiation conditions. The yields of the sulfonamides are more than 90%. The synthesized 4-(substituted phenylsulfonamido) benzoic acid derivatives were characterized by their physical constants
    通过粉煤灰:H3PO3纳米催化剂在超声辐射条件下催化取代苯磺酰氯与4-氨基苯甲酸的缩合反应,合成了一些4-(取代苯基磺酰胺基)苯甲酸。磺酰胺的产率超过90%。合成的4-(取代的苯磺酰胺基)苯甲酸衍生物的物理常数,分析数据和光谱数据均得到了表征。所有磺酰胺类药物的抗菌活性均通过Bauer-Kirby纸片扩散法进行测定。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐